

David P Nicolau

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4381899/david-p-nicolau-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

367
papers

6,587
citations

41
h-index

62
g-index

391
ext. papers

8,023
ext. citations

5
avg, IF

6.85
L-index

#	Paper	IF	Citations
367	Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 1725-30	5.9	208
366	Pharmacokinetic and pharmacodynamic properties of meropenem. <i>Clinical Infectious Diseases</i> , 2008 , 47 Suppl 1, S32-40	11.6	132
365	Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. <i>Journal of Clinical Pharmacology</i> , 2006 , 46, 1171-8	2.9	118
364	Carbapenems: a potent class of antibiotics. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 23-37	4	114
363	Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. <i>Journal of Clinical Pharmacology</i> , 2016 , 56, 56-66	2.9	114
362	Increased 3-gram cefazolin dosing for cesarean delivery prophylaxis in obese women. <i>American Journal of Obstetrics and Gynecology</i> , 2015 , 213, 415.e1-8	6.4	98
361	Clinical pharmacodynamics of cefepime in patients infected with <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 1111-6	5.9	89
360	Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 1476-81	5.9	89
359	Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo- β -lactamase producers. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 3299-306	5.9	85
358	Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2005 , 56, 388-95	5.1	81
357	1544. Efficacy of Human-Simulated Cefiderocol Exposure Against Gram-Negative Bacteria in an Iron-Overloaded Murine Thigh Infection Model. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S563-S563	1	78
356	Intracellular and Extracellular Penetration of Azithromycin into Inflammatory and Noninflammatory Blister Fluid. <i>Antimicrobial Agents and Chemotherapy</i> , 1995 , 39, 795-795	5.9	78
355	1533. Is Cation-Adjusted Mueller-Hinton Broth (CAMHB) Appropriate for Metallo- β -lactamase (MBL) Susceptibility Testing? Novel Insights in In Vitro-In Vivo Discordance Among MBL-Producing Enterobacteriaceae. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S558-S559	1	78
354	675. Efficacy of Human-Simulated Bronchopulmonary Exposures of Cefepime and Zidebactam (WCK 5222) Against Multidrug-Resistant (MDR) <i>Pseudomonas aeruginosa</i> (PSA) in a Neutropenic Murine Pneumonia Model. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S308-S308	1	78
353	725. WCK 5222 (Cefepime/Zidebactam): An In Vitro Assessment of Activity Compared with Current Dual-Antibiotic Options Against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> . <i>Open Forum Infectious Diseases</i> , 2019 , 6, S325-S325	1	78
352	1553. Human-Simulated Pharmacokinetic Profiles of Cefiderocol and Meropenem Are Conserved in Murine Models of Thigh Infection With or Without Iron Overload. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S567-S567	1	78
351	685. An In Vitro Investigation of WCK 5222 (Cefepime/Zidebactam) and Currently Available Combination Antibiotic Regimens Against Enterobacteriaceae That Co-express Serine- β -lactamase (SBL) and Metallo- β -lactamase (MBL) Enzymes. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S311-S312	1	78

350	450. Evaluation of Linezolid Pharmacokinetics in Obese Patients with Severe Skin and Soft-Tissue Infections. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S221-S221	1	78
349	1397. Comparative Efficacy of Human-Simulated Epithelial Lining Fluid (ELF) Exposures of Tedizolid (TZD) Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Neutropenic (I) vs. Immunocompetent (I+) Murine Models of Pneumonia. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S430-S430	1	78
348	2175. In vitro Potency of Ceftolozane/Tazobactam and Other Antipseudomonal β Lactams Against <i>P. aeruginosa</i> . <i>Open Forum Infectious Diseases</i> , 2018 , 5, S642-S642	1	78
347	2176. Single β Lactams v. Combination Regimens: Assessing the Probability that an Active Agent Would be Selected When Considering Empiric Therapy for <i>P. aeruginosa</i> . <i>Open Forum Infectious Diseases</i> , 2018 , 5, S642-S643	1	78
346	2388. Efficacy of Humanized Cefiderocol Exposures Over 72 Hours Against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S712-S712	1	78
345	Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2862-9	5.1	75
344	Optimization of meropenem dosage in the critically ill population based on renal function. <i>Intensive Care Medicine</i> , 2011 , 37, 632-8	14.5	69
343	The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship. <i>Intensive Care Medicine</i> , 2017 , 43, 1187-1197	14.5	66
342	Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling. <i>Journal of Infection and Chemotherapy</i> , 2003 , 9, 292-6	2.2	63
341	Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	58
340	Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 1359-64	5.9	55
339	Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in <i>Pseudomonas aeruginosa</i> : Assessing the Risk for Resistance and Attenuated Efficacy. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 7743-52	5.9	52
338	In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 874-9	5.9	52
337	Pharmacokinetics of dalbavancin in plasma and skin blister fluid. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 60, 681-4	5.1	51
336	Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 1144-9	5.9	50
335	In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 3220-5	5.9	50
334	Prolonging β Lactam infusion: a review of the rationale and evidence, and guidance for implementation. <i>International Journal of Antimicrobial Agents</i> , 2014 , 43, 105-13	14.3	49
333	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> in a neutropenic mouse thigh model. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 1481-6	5.9	48

332	Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible <i>Pseudomonas aeruginosa</i> from Blood, Respiratory Tract, and Wounds. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	48
331	Efficacies of ceftazidime-avibactam and ceftazidime against <i>Pseudomonas aeruginosa</i> in a murine lung infection model. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 1365-71	5.9	47
330	Carbapenem stewardship: does ertapenem affect <i>Pseudomonas</i> susceptibility to other carbapenems? A review of the evidence. <i>International Journal of Antimicrobial Agents</i> , 2012 , 39, 11-5	14.3	47
329	Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient. <i>Annals of Intensive Care</i> , 2016 , 6, 35	8.9	47
328	Comparative in vivo efficacy of meropenem, imipenem, and cefepime against <i>Pseudomonas aeruginosa</i> expressing MexA-MexB-OprM efflux pumps. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007 , 57, 153-61	2.9	44
327	Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against <i>Escherichia coli</i> , <i>Klebsiella pneumoniae</i> , and <i>Pseudomonas aeruginosa</i> From US Hospitals. <i>Clinical Therapeutics</i> , 2015 , 37, 1564-71	3.5	43
326	In vivo activities of simulated human doses of cefepime and cefepime-AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 2688-94	5.9	41
325	infection in the elderly: an update on management. <i>Clinical Interventions in Aging</i> , 2017 , 12, 1799-1809	4	40
324	Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infections. <i>Journal of Infection</i> , 2007 , 54, 463-8	18.9	40
323	Pharmacodynamic optimization of beta-lactams in the patient care setting. <i>Critical Care</i> , 2008 , 12 Suppl 4, S2	10.8	38
322	Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial. <i>Lancet Infectious Diseases</i> , 2020 , 20, 330-340	25.5	38
321	Impact of the New Delhi metallo-beta-lactamase on beta-lactam antibiotics. <i>Infection and Drug Resistance</i> , 2015 , 8, 297-309	4.2	37
320	Clinical and economic implications of antimicrobial resistance for the management of community-acquired respiratory tract infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2002 , 50 Suppl S1, 61-70	5.1	36
319	Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 60, 1401-10	5.9	35
318	Ceftolozane/Tazobactam Pharmacokinetics in a Critically Ill Adult Receiving Continuous Renal Replacement Therapy. <i>Pharmacotherapy</i> , 2016 , 36, e30-e33	5.8	35
317	Use of a bioabsorbable polymer for the delivery of ofloxacin during experimental osteomyelitis treatment. <i>Journal of Orthopaedic Research</i> , 1998 , 16, 76-9	3.8	34
316	Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam. <i>Pharmacotherapy</i> , 2002 , 22, 569-77	5.8	34
315	Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a <i>Pseudomonas aeruginosa</i> neutropenic murine thigh model. <i>International Journal of Antimicrobial Agents</i> , 2018 , 51, 206-212	14.3	33

314	Pharmacodynamic assessment of cefprozil against <i>Streptococcus pneumoniae</i> : implications for breakpoint determinations. <i>Antimicrobial Agents and Chemotherapy</i> , 2000 , 44, 1291-5	5.9	33
313	Clinical pharmacokinetics of newer cephalosporins. <i>Clinical Pharmacokinetics</i> , 1995 , 28, 361-84	6.2	33
312	Continuous and Prolonged Intravenous β -Lactam Dosing: Implications for the Clinical Laboratory. <i>Clinical Microbiology Reviews</i> , 2016 , 29, 759-72	34	32
311	Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens. <i>International Journal of Antimicrobial Agents</i> , 2016 , 48, 535-541	14.3	32
310	Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 60, 1899-901	5.9	32
309	Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against <i>Pseudomonas aeruginosa</i> isolated from children with cystic fibrosis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015 , 83, 53-5	2.9	31
308	Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 6578-6584	5.9	31
307	Treatment of multidrug-resistant <i>Pseudomonas aeruginosa</i> with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration. <i>International Journal of Antimicrobial Agents</i> , 2016 , 48, 342-3	14.3	31
306	Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant <i>Staphylococcus aureus</i> collected from US hospitals. <i>International Journal of Antimicrobial Agents</i> , 2014 , 44, 235-41	14.3	31
305	In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 6913-9	5.9	31
304	In vitro elution of ofloxacin from a bioabsorbable polymer. <i>Acta Orthopaedica</i> , 1995 , 66, 365-8		31
303	Antibacterial Efficacy of Eravacycline In Vivo against Gram-Positive and Gram-Negative Organisms. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 5001-5	5.9	30
302	Efficacy of Meropenem with a Novel Non- β -Lactam- β -Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	30
301	Empiric treatment of multidrug-resistant <i>Burkholderia cepacia</i> lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy. <i>Pharmacotherapy</i> , 2004 , 24, 1641-5	5.8	30
300	In vivo efficacy of human simulated regimens of carbapenems and comparator agents against NDM-1-producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 1671-7	5.9	29
299	Efficacy of humanized carbapenem exposures against New Delhi metallo- β -lactamase (NDM-1)-producing enterobacteriaceae in a murine infection model. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 3936-40	5.9	29
298	Therapeutic options for diabetic foot infections: a review with an emphasis on tissue penetration characteristics. <i>Journal of the American Podiatric Medical Association</i> , 2010 , 100, 52-63	1	29
297	Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts. <i>American Journal of Health-System Pharmacy</i> , 2003 , 60, 565-8	2.2	29

296	Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 942-952 ^{5.1}	5.1	28
295	Unexpected in vivo activity of ceftazidime alone and in combination with avibactam against New Delhi metallo-β-lactamase-producing Enterobacteriaceae in a murine thigh infection model. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 7007-9	5.9	28
294	Diagnostic and medical needs for therapeutic drug monitoring of antibiotics. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020 , 39, 791-797	5.3	28
293	Assessment of the Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant <i>Acinetobacter baumannii</i> in the Neutropenic Murine Lung Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	28
292	Cefepime dosing in the morbidly obese patient population. <i>Obesity Surgery</i> , 2012 , 22, 465-71	3.7	27
291	Comparison of Ceftolozane-Tazobactam to Traditional Beta-Lactams and Ceftolozane-Tazobactam as an Alternative to Combination Antimicrobial Therapy for <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	27
290	In Vitro Activity of Cefepime/AAI101 and Comparators against Cefepime Non-susceptible Enterobacteriaceae. <i>Pathogens</i> , 2015 , 4, 620-5	4.5	27
289	Activities of clarithromycin, azithromycin, and ofloxacin in combination with liposomal or unencapsulated granulocyte-macrophage colony-stimulating factor against intramacrophage <i>Mycobacterium avium-Mycobacterium intracellulare</i> . <i>Journal of Infectious Diseases</i> , 1995 , 172, 810-6	7	27
288	Development of an HPLC Method for the Determination of Ceftolozane/Tazobactam in Biological and Aqueous Matrixes. <i>Journal of Chromatographic Science</i> , 2016 , 54, 1037-40	1.4	27
287	Evaluation of the EDTA-Modified Carbapenem Inactivation Method for Detecting Metallo-β-lactamase-Producing. <i>Journal of Clinical Microbiology</i> , 2020 , 58,	9.7	26
286	Humanized Exposures of Cefiderocol, a Siderophore Cephalosporin, Display Sustained in vivo Activity against Siderophore-Resistant <i>Pseudomonas aeruginosa</i> . <i>Pharmacology</i> , 2018 , 101, 278-284	2.3	26
285	Potential of antibacterial activity of the MB-1 siderophore-monobactam conjugate using an efflux pump inhibitor. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 2439-42	5.9	26
284	Current challenges in the management of the infected patient. <i>Current Opinion in Infectious Diseases</i> , 2011 , 24 Suppl 1, S1-10	5.4	26
283	Metallo-β-lactamase resistance in Enterobacteriaceae is an artefact of currently utilized antimicrobial susceptibility testing methods. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 997-1005 ^{5.1}	5.1	25
282	Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004. <i>International Journal of Antimicrobial Agents</i> , 2007 , 30, 452-7	14.3	25
281	Effects of Urine Matrix and pH on the Potency of Delafloxacin and Ciprofloxacin against Urogenic <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> . <i>Journal of Urology</i> , 2015 , 194, 563-70	2.5	24
280	Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1546-1553	5.1	24
279	Carbapenem-Resistant Enterobacteriales, Carbapenem Resistant Organisms, Carbapenemase-Producing Enterobacteriales, and Carbapenemase-Producing Organisms: Terminology Past its "Sell-By Date" in an Era of New Antibiotics and Regional Carbapenemase Epidemiology. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1776-1788	11.6	24

278	Review of antimicrobial use and considerations in the elderly population. <i>Clinical Interventions in Aging</i> , 2018 , 13, 657-667	4	24
277	Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 1213-22	4	24
276	Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology. <i>Current Infectious Disease Reports</i> , 2020 , 22, 6	3.9	23
275	Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteria. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 325-338	5.9	23
274	Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: Defining the zone of hope. <i>International Journal of Antimicrobial Agents</i> , 2018 , 52, 688-691	14.3	23
273	Meropenem administered as a prolonged infusion to treat serious gram-negative central nervous system infections. <i>Pharmacotherapy</i> , 2004 , 24, 803-7	5.8	23
272	Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections. <i>Therapeutics and Clinical Risk Management</i> , 2016 , 12, 1811-1826	2.9	23
271	Making a Case for Pediatric Antimicrobial Stewardship Programs. <i>Pharmacotherapy</i> , 2015 , 35, 1026-36	5.8	22
270	Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint. <i>Clinical Infectious Diseases</i> , 2019 , 68, 1650-1657	11.6	22
269	Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients. <i>Surgical Infections</i> , 2019 , 20, 55-61	2	22
268	Carbapenem-Nonsusceptible Isolates from Intensive Care Units in the United States: a Potential Role for New β -Lactam Combination Agents. <i>Journal of Clinical Microbiology</i> , 2019 , 57,	9.7	21
267	Eravacycline Pharmacokinetics and Challenges in Defining Humanized Exposure In Vivo. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 5072-5	5.9	21
266	Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 459-76	3.8	21
265	Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant in the Neutropenic Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	21
264	Efficacy of Humanized WCK 5222 (Cefepime-Zidebactam) Exposures against Carbapenem-Resistant <i>Acinetobacter baumannii</i> in the Neutropenic Thigh Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	21
263	Treatment of <i>Serratia marcescens</i> meningitis with prolonged infusion of meropenem. <i>Annals of Pharmacotherapy</i> , 2007 , 41, 1077-81	2.9	20
262	Successful Treatment of Multi-Drug Resistant <i>Pseudomonas aeruginosa</i> Bacteremia with the Recommended Renally Adjusted Ceftolozane/Tazobactam Regimen. <i>Infectious Diseases and Therapy</i> , 2016 , 5, 73-9	6.2	20
261	Comparative Antibacterial Activity of Human-Simulated Exposures of Cefiderocol and Ceftazidime against in the Murine Thigh Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 ,	5.9	20

260	Population Pharmacokinetics of Cefazolin in Serum and Adipose Tissue From Overweight and Obese Women Undergoing Cesarean Delivery. <i>Journal of Clinical Pharmacology</i> , 2017 , 57, 712-719	2.9	19
259	An exploratory analysis of the ability of a cefepime trough concentration greater than 22 mg/L to predict neurotoxicity. <i>Journal of Infection and Chemotherapy</i> , 2016 , 22, 78-83	2.2	19
258	Antibiotic Utilization and Opportunities for Stewardship Among Hospitalized Patients With Influenza Respiratory Tract Infection. <i>Infection Control and Hospital Epidemiology</i> , 2016 , 37, 583-9	2	19
257	Use of ceftolozane-tazobactam in a cystic fibrosis patient with multidrug-resistant pseudomonas infection and renal insufficiency. <i>Respiratory Medicine Case Reports</i> , 2018 , 23, 8-9	1.2	19
256	Cost comparison of single daily i.v. doses of ceftriaxone versus continuous infusion of cefotaxime. <i>American Journal of Health-System Pharmacy</i> , 1997 , 54, 1614-8	2.2	18
255	Pharmacodynamics of antimicrobials: treatment optimisation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2005 , 1, 351-61	5.5	18
254	In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2016 , 15, 39	6.2	18
253	Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	18
252	Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant Pseudomonas aeruginosa in an Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	17
251	Epidemiology and economics of adult patients hospitalized with urinary tract infections. <i>Hospital Practice (1995)</i> , 2016 , 44, 33-40	2.2	17
250	Pharmacodynamic Profile of GSK2140944 against Methicillin-Resistant Staphylococcus aureus in a Murine Lung Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 4956-61	5.9	17
249	Augmented Renal Clearance and How to Augment Antibiotic Dosing. <i>Antibiotics</i> , 2020 , 9,	4.9	17
248	Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 5627-30	5.9	17
247	Efficacy of Humanized Cefiderocol Exposures over 72 Hours against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	17
246	Epidemiology, treatment, and economics of patients presenting to the emergency department for skin and soft tissue infections. <i>Hospital Practice (1995)</i> , 2017 , 45, 9-15	2.2	16
245	Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 149-155	5.1	16
244	Discovery and Characterization of a Water-Soluble Prodrug of a Dual Inhibitor of Bacterial DNA Gyrase and Topoisomerase IV. <i>ACS Medicinal Chemistry Letters</i> , 2015 , 6, 822-6	4.3	16
243	Pharmacodynamics of carbapenems for the treatment of Pseudomonas aeruginosa ventilator-associated pneumonia: associations with clinical outcome and recurrence. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 2534-7	5.1	16

242	Pharmacokinetics and Pharmacodynamics of Continuous and Intermittent Ceftazidime during the Treatment of Nosocomial Pneumonia. <i>Clinical Drug Investigation</i> , 1999 , 18, 133-139	3.2	16
241	Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 189-95	5.1	15
240	In vitro Activity of Ceftolozane/Tazobactam Alone or with an Aminoglycoside Against Multi-Drug-Resistant <i>Pseudomonas aeruginosa</i> from Pediatric Cystic Fibrosis Patients. <i>Infectious Diseases and Therapy</i> , 2017 , 6, 129-136	6.2	15
239	Development of Daptomycin Susceptibility Breakpoints for <i>Enterococcus faecium</i> and Revision of the Breakpoints for Other Enterococcal Species by the Clinical and Laboratory Standards Institute. <i>Clinical Infectious Diseases</i> , 2020 , 70, 1240-1246	11.6	15
238	In vitro synergy of ceftolozane/tazobactam in combination with fosfomycin or aztreonam against MDR <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1874-1878	5.1	15
237	Novel pharmacotherapy for the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 397-408	4	15
236	To add or not to add polysorbate 80: impact on colistin MICs for clinical strains of Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> and quality controls. <i>Journal of Clinical Microbiology</i> , 2014 , 52, 3810	9.7	15
235	In vitro activity of human-simulated epithelial lining fluid exposures of ceftaroline, ceftriaxone, and vancomycin against methicillin-susceptible and -resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 7520-6	5.9	15
234	A guide to therapeutic drug monitoring of β -lactam antibiotics. <i>Pharmacotherapy</i> , 2021 , 41, 220-233	5.8	15
233	Use of continuous infusion ceftolozane-tazobactam with therapeutic drug monitoring in a patient with cystic fibrosis. <i>American Journal of Health-System Pharmacy</i> , 2019 , 76, 501-504	2.2	14
232	Vancomycin serum concentrations do not adequately predict tissue exposure in diabetic patients with mild to moderate limb infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2064-7	5.1	14
231	Efficacy of humanized high-dose meropenem, cefepime, and levofloxacin against Enterobacteriaceae isolates producing Verona integron-encoded metallo- β -lactamase (VIM) in a murine thigh infection model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 7145-7	5.9	14
230	Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic/pharmacodynamic analysis. <i>International Journal of Antimicrobial Agents</i> , 2018 , 51, 727-732	14.3	14
229	Transitions of care in the management of acute bacterial skin and skin structure infections: a paradigm shift. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 1039-45	3.8	14
228	Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact Analysis. <i>Clinical Drug Investigation</i> , 2016 , 36, 157-68	3.2	14
227	Efficacy of Plazomicin Alone or in Combination with Meropenem or Tigecycline against Enterobacteriaceae Isolates Exhibiting Various Resistance Mechanisms in an Immunocompetent Murine Septicemia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	14
226	Assessment of the Activity of SPR741 in Combination with Azithromycin against Multidrug-Resistant Enterobacteriaceae Isolates in the Neutropenic Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	14
225	Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2012 , 25, 94-8	3.5	14

224	Pharmacodynamics of a novel des-F(6)-quinolone, BMS-284756, against <i>Streptococcus pneumoniae</i> in the thigh infection model. <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 1630-5	5.9	14
223	Assessment of <i>Clostridium difficile</i> Burden in Patients Over Time With First Episode Infection Following Fidaxomicin or Vancomycin. <i>Infection Control and Hospital Epidemiology</i> , 2016 , 37, 215-8	2	14
222	Comparative In Vivo Efficacies of Tedizolid in Neutropenic versus Immunocompetent Murine <i>Streptococcus pneumoniae</i> Lung Infection Models. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	13
221	Pharmacodynamic Profile of Ceftibuten-Clavulanate Combination against Extended-Spectrum- β -Lactamase-Producing Enterobacteriaceae in the Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	13
220	Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 428-37	5.1	13
219	Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	13
218	Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: a 'Goldilocks' window. <i>International Journal of Antimicrobial Agents</i> , 2017 , 50, 487-490	14.3	13
217	Population pharmacokinetics of continuous infusion ceftazidime. <i>Clinical Pharmacokinetics</i> , 1999 , 37, 343-50	6.2	13
216	Meropenem-nacubactam activity against AmpC-overproducing and KPC-expressing <i>Pseudomonas aeruginosa</i> in a neutropenic murine lung infection model. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105838	14.3	13
215	The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant <i>Pseudomonas aeruginosa</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021 , 40, 2533-2541	5.3	13
214	Obesity and skin and soft tissue infections: how to optimize antimicrobial usage for prevention and treatment?. <i>Current Opinion in Infectious Diseases</i> , 2017 , 30, 180-191	5.4	12
213	Efficacy of Human-Simulated Epithelial Lining Fluid Exposure of Meropenem-Nacubactam Combination against Class A Serine β -Lactamase-Producing in the Neutropenic Murine Lung Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	12
212	Impact of vancomycin faecal concentrations on clinical and microbiological outcomes in <i>Clostridium difficile</i> infection. <i>International Journal of Antimicrobial Agents</i> , 2015 , 46, 205-8	14.3	12
211	Comparative Evaluation of the Activities of WCK 5222 (Cefepime-Zidebactam) and Combination Antibiotic Therapies against Carbapenem-Resistant. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	12
210	Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: Part I gram positive bacteria. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 267-80	5.5	12
209	Pharmacodynamics of Daptomycin against <i>Enterococcus faecium</i> and <i>Enterococcus faecalis</i> in the Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	12
208	Pharmacokinetics-pharmacodynamics of β -Lactamase inhibitors: are we missing the target?. <i>Expert Review of Anti-Infective Therapy</i> , 2019 , 17, 571-582	5.5	12
207	Pharmacodynamics and tolerability of high-dose, prolonged infusion carbapenems in adults with cystic fibrosis [A review of 3 cases. <i>Respiratory Medicine CME</i> , 2010 , 3, 146-149		12

206	Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation. <i>Clinical Therapeutics</i> , 2007 , 29, 889-899	3.5	12
205	Choosing between the new cephalosporin antibiotics: a pharmacodynamic approach. <i>Pharmacoeconomics</i> , 1994 , 5, 34-9	4.4	12
204	Use of Oritavancin in Moderate-to-Severe ABSSSI Patients Requiring IV Antibiotics: A U.S. Payer Budget Impact Analysis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016 , 22, 752-64	1.9	12
203	In vitro activity of ampicillin and ceftriaxone against ampicillin-susceptible <i>Enterococcus faecium</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 2269-2273	5.1	11
202	Impact of revised cefepime CLSI breakpoints on <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> susceptibility and potential impact if applied to <i>Pseudomonas aeruginosa</i> . <i>Journal of Clinical Microbiology</i> , 2015 , 53, 1712-4	9.7	11
201	Defining the potency of amikacin against , and derived from Chinese hospitals using CLSI and inhalation-based breakpoints. <i>Infection and Drug Resistance</i> , 2018 , 11, 783-790	4.2	11
200	Management of Pediatric Acute Hematogenous Osteomyelitis, Part I: Antimicrobial Stewardship Approach and Review of Therapies for Methicillin-Susceptible <i>Staphylococcus aureus</i> , <i>Streptococcus pyogenes</i> , and <i>Kingella kingae</i> . <i>Pharmacotherapy</i> , 2018 , 38, 947-966	5.8	11
199	Pharmacokinetics and Tissue Penetration of Ceftolozane-Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	11
198	Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant <i>Pseudomonas aeruginosa</i> . <i>Journal of Medical Microbiology</i> , 2019 , 68, 893-897	3.2	11
197	Variability in Zinc Concentration among Mueller-Hinton Broth Brands: Impact on Antimicrobial Susceptibility Testing of Metallo- β -Lactamase-Producing. <i>Journal of Clinical Microbiology</i> , 2020 , 58,	9.7	11
196	Efficacy of Humanized Cefiderocol Exposure Is Unaltered by Host Iron Overload in the Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 64,	5.9	11
195	Comparative Assessment of Tedizolid Pharmacokinetics and Tissue Penetration between Diabetic Patients with Wound Infections and Healthy Volunteers via Microdialysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	11
194	Meropenem time above the MIC exposure is predictive of response in cystic fibrosis children with acute pulmonary exacerbations. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018 , 91, 294-297	2.9	10
193	Physical Compatibility of Meropenem and Vaborbactam With Select Intravenous Drugs During Simulated Y-site Administration. <i>Clinical Therapeutics</i> , 2018 , 40, 261-269	3.5	10
192	Clinical and economic implications of urinary tract infections. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017 , 17, 377-383	2.2	10
191	Population Pharmacokinetics of Cefazolin in Serum and Tissue for Patients with Complicated Skin and Soft Tissue Infections (cSSTI). <i>Infectious Diseases and Therapy</i> , 2014 , 3, 269-79	6.2	10
190	Lomefloxacin clinical pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 1993 , 25, 6-19	6.2	10
189	Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Novel Therapy for Multidrug Resistant Gram Negative Infections in Children. <i>Current Pediatric Reviews</i> , 2018 , 14, 97-109	2.8	10

188	Evaluation of the in vitro activity of WCK 5222 (cefepime/zidebactam) and currently available combination therapies against single- and double-carbapenemase producing Enterobacteriaceae: Expanding the zone of hope. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105863	14.3	10
187	In vivo pharmacodynamics of new-generation β -lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine- β -lactamase-producing Gram-negative bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 3601-3610	5.1	10
186	Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance. <i>International Journal of Antimicrobial Agents</i> , 2021 , 57, 106299	14.3	10
185	Can we improve clinical outcomes in patients with pneumonia treated with antibiotics in the intensive care unit?. <i>Expert Review of Respiratory Medicine</i> , 2016 , 10, 907-18	3.8	10
184	Clinical pathway for moderate to severe acute bacterial skin and skin structure infections from a US perspective: a roundtable discussion. <i>Hospital Practice (1995)</i> , 2016 , 44, 183-189	2.2	9
183	A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2016 , 15, 22	6.2	9
182	Effect of Body Weight on Cefazolin and Vancomycin Trabecular Bone Concentrations in Patients Undergoing Total Joint Arthroplasty. <i>Surgical Infections</i> , 2016 , 17, 71-7	2	9
181	Clinafloxacin for Treatment of Burkholderia cenocepacia Infection in a Cystic Fibrosis Patient. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 1-5	5.9	9
180	Antibacterial Activity of Human Simulated Epithelial Lining Fluid Concentrations of Ceftazidime-Avibactam Alone or in Combination with Amikacin Inhale (BAY41-6551) against Carbapenem-Resistant Pseudomonas aeruginosa and Klebsiella pneumoniae. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62	5.9	9
179	Management of Pediatric Acute Hematogenous Osteomyelitis, Part II: A Focus on Methicillin-Resistant Staphylococcus aureus, Current and Emerging Therapies. <i>Pharmacotherapy</i> , 2018 , 38, 1021-1037	5.8	9
178	Comparative efficacy of linezolid and vancomycin for endotracheal tube MRSA biofilms from ICU patients. <i>Critical Care</i> , 2019 , 23, 251	10.8	9
177	Comparison of in vivo and in vitro pharmacodynamics of a humanized regimen of 600 milligrams of Ceftaroline Fosamil every 12 hours against Staphylococcus aureus at initial inocula of 106 and 108 CFU per milliliter. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 6931-3	5.9	9
176	Pharmacokinetics of cefprozil in plasma and middle ear fluid: in children undergoing treatment for acute otitis media. <i>Paediatric Drugs</i> , 2007 , 9, 119-23	4.2	9
175	Influence of sex on the pharmacokinetic interaction of fleroxacin and ciprofloxacin with caffeine. <i>Clinical Pharmacokinetics</i> , 2003 , 42, 985-96	6.2	9
174	Synergistic Activity of Exebacase (CF-301) in Addition to Daptomycin against Staphylococcus aureus in a Neutropenic Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	9
173	Use of continuous-infusion ceftolozane/tazobactam for resistant Gram-negative bacterial infections: a retrospective analysis and brief review of the literature. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106158	14.3	9
172	Activity of β -Lactam Antibiotics against Metallo- β -Lactamase-Producing in Animal Infection Models: a Current State of Affairs. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65,	5.9	9
171	Development of Neutropenic Murine Models of Iron Overload and Depletion To Study the Efficacy of Siderophore-Antibiotic Conjugates. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 64,	5.9	9

170	Patient preferences for treatment of acute bacterial skin and skin structure infections in the emergency department. <i>BMC Health Services Research</i> , 2018 , 18, 932	2.9	9
169	Epidemiology of Bloodstream Infections Caused by and That Are Piperacillin-Tazobactam-Nonsusceptible but Ceftriaxone-Susceptible. <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofy300	1	9
168	Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: part II Gram-negative bacteria. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 705-714	5.5	8
167	Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 1261-73	5.9	8
166	Potency of parenteral antimicrobials including ceftolozane/tazobactam against nosocomial respiratory tract pathogens: considerations for empiric and directed therapy. <i>Journal of Thoracic Disease</i> , 2017 , 9, 214-221	2.6	8
165	Evaluation of Plazomicin, Tigecycline, and Meropenem Pharmacodynamic Exposure against Carbapenem-Resistant Enterobacteriaceae in Patients with Bloodstream Infection or Hospital-Acquired/Ventilator-Associated Pneumonia from the CARE Study (ACHN-490-007). <i>Infectious Diseases and Therapy</i> , 2018 , 9, 283-294	6.2	8
164	Cefazolin potency against methicillin-resistant : a microbiologic assessment in support of a novel drug delivery system for skin and skin structure infections. <i>Infection and Drug Resistance</i> , 2017 , 10, 227-230	4.3	8
163	Successful application of serum shift prediction models to the design of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV with improved in vivo efficacy. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014 , 24, 2177-81	2.9	8
162	Employing pharmacokinetic and pharmacodynamic principles to optimize antimicrobial treatment in the face of emerging resistance. <i>Brazilian Journal of Microbiology</i> , 2007 , 38, 183-193	2.2	8
161	Clinical use of antimicrobial pharmacodynamic profiles to optimise treatment outcomes in community-acquired bacterial respiratory tract infections: application to telithromycin. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 229-35	4	8
160	Piperacillin-Tazobactam-Resistant/Third-Generation Cephalosporin-Susceptible Escherichia coli and Klebsiella pneumoniae Isolates: Resistance Mechanisms and In vitro-In vivo Discordance. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105885	14.3	8
159	The paradoxical in vivo activity of β -lactams against metallo- β -lactamase-producing Enterobacterales is not restricted to carbapenems. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 684-691	5.1	8
158	In Vitro Activity of Newer and Conventional Antimicrobial Agents, Including Fosfomycin and Colistin, against Selected Gram-Negative Bacilli in Kuwait. <i>Pathogens</i> , 2018 , 7,	4.5	8
157	Pharmacodynamics of a Novel Ceftibuten-Clavulanate Combination Antibiotic against Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	7
156	potency of antipseudomonal β -lactams against blood and respiratory isolates of collected from US hospitals. <i>Journal of Thoracic Disease</i> , 2019 , 11, 1896-1902	2.6	7
155	A Simulated Application of the Hartford Hospital Aminoglycoside Dosing Nomogram for Plazomicin Dosing Interval Selection in Patients With Serious Infections Caused by Carbapenem-Resistant Enterobacterales. <i>Clinical Therapeutics</i> , 2019 , 41, 1453-1462	3.5	7
154	Ceftolozane-Tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Mechanisms of Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	7
153	Development and Application of a Pragmatic Algorithm to Guide Definitive Carbapenemase Testing to Identify Carbapenemase-Producing. <i>Antibiotics</i> , 2020 , 9,	4.9	7

152	Nebulized Amikacin and Fosfomycin for Severe <i>Pseudomonas aeruginosa</i> Pneumonia: An Experimental Study. <i>Critical Care Medicine</i> , 2019 , 47, e470-e477	1.4	7
151	Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2018 , 75, e36-e44	2.2	7
150	Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2902-2905	5.1	7
149	Effects of Clinically Meaningful Concentrations of Antipseudomonal β -Lactams on Time to Detection and Organism Growth in Blood Culture Bottles. <i>Journal of Clinical Microbiology</i> , 2017 , 55, 3502-3512 ⁶	9.7	6
148	Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients. <i>International Journal of Antimicrobial Agents</i> , 2015 , 45, 512-8	14.3	6
147	Clinical pharmacokinetics of ceftolozane and tazobactam in an obese patient receiving continuous venovenous haemodiafiltration: A patient case and literature review. <i>Journal of Global Antimicrobial Resistance</i> , 2020 , 21, 83-85	3.4	6
146	Feasibility of routine synergy testing using antibiotic gradient diffusion strips in the clinical laboratory. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 2264-2265	5.1	6
145	Assessing the Surrogate Susceptibility of Oxacillin and Cefoxitin for Commonly Utilized Parenteral Agents against Methicillin-Susceptible <i>Staphylococcus aureus</i> : Focus on Ceftriaxone Discordance between Predictive Susceptibility and in Vivo Exposures. <i>Pathogens</i> , 2015 , 4, 599-605	4.5	6
144	Evaluation of the Xpert Carba-R NxG Assay for Detection of Carbapenemase Genes in a Global Challenge Set of <i>Pseudomonas aeruginosa</i> Isolates. <i>Journal of Clinical Microbiology</i> , 2020 , 58,	9.7	6
143	Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2018 , 75, 1048-1056	2.2	6
142	Isolation and quantitation of <i>Clostridium difficile</i> in aqueous and fecal matter using two types of selective media. <i>Journal of Microbiology, Immunology and Infection</i> , 2016 , 49, 445-7	8.5	5
141	Effect of Clinically Meaningful Antibiotic Concentrations on Recovery of <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> Isolates from Anaerobic Blood Culture Bottles with and without Antibiotic Binding Resins. <i>Journal of Clinical Microbiology</i> , 2019 , 57,	9.7	5
140	In vitro investigation of synergy among fosfomycin and parenteral antimicrobials against carbapenemase-producing Enterobacteriaceae. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019 , 95, 216-220	2.9	5
139	In vivo activity of human-simulated regimens of imipenem alone and in combination with relebactam against <i>Pseudomonas aeruginosa</i> in the murine thigh infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 2197-2205	5.1	5
138	Physical compatibility of tedizolid phosphate with selected i.v. drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2016 , 73, 1769-1776	2.2	5
137	Poor outcomes of empiric ceftriaxone+azithromycin for community-acquired pneumonia caused by methicillin-susceptible <i>Staphylococcus aureus</i> . <i>Internal and Emergency Medicine</i> , 2016 , 11, 545-51	3.7	5
136	Application of the Hartford Hospital Nomogram for Plazomicin Dosing Interval Selection in Patients with Complicated Urinary Tract Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	5
135	Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia. <i>International Journal of Antimicrobial Agents</i> , 2019 , 54, 346-350	14.3	5

134	Translational Efficacy of Humanized Exposures of Cefepime, Ertapenem, and Levofloxacin against Extended-Spectrum- β -Lactamase-Producing <i>Escherichia coli</i> in a Murine Model of Complicated Urinary Tract Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	5
133	Antibacterial activity of human simulated epithelial lining fluid concentrations of amikacin inhale alone and in combination with meropenem against <i>Acinetobacter baumannii</i> . <i>Infectious Diseases</i> , 2017 , 49, 831-839	3.1	5
132	Lack of Correlation between Bristol Stool Scale and Quantitative Bacterial Load in <i>Clostridium difficile</i> Infection. <i>Infectious Diseases: Research and Treatment</i> , 2015 , 8, 1-4	3.1	5
131	Stability of ertapenem 100 mg/mL in polypropylene syringes stored at 25, 4, and -20 °C. <i>American Journal of Health-System Pharmacy</i> , 2014 , 71, 1480-4	2.2	5
130	Pharmacoeconomics of <i>Pneumocystis carinii</i> pneumonia in HIV-infected and HIV-noninfected patients. <i>Pharmacoeconomics</i> , 1996 , 10, 72-8	4.4	5
129	Management of Pneumonia in the Pediatric Critical Care Unit: An Area for Antimicrobial Stewardship. <i>Current Pediatric Reviews</i> , 2017 , 13, 49-66	2.8	5
128	Monte Carlo Simulation Methodologies for β -Lactam/ β -Lactamase Inhibitor Combinations: Effect on Probability of Target Attainment Assessments. <i>Journal of Clinical Pharmacology</i> , 2020 , 60, 172-180	2.9	5
127	EDTA-modified carbapenem inactivation method (eCIM) for detecting IMP Metallo- β -Lactamase-producing <i>Pseudomonas aeruginosa</i> : an assessment of increasing EDTA concentrations. <i>BMC Microbiology</i> , 2020 , 20, 220	4.5	5
126	Discrepancy in sustained efficacy and resistance emergence under human-simulated exposure of cefiderocol against <i>Stenotrophomonas maltophilia</i> between in vitro chemostat and in vivo murine infection models. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2615-2621	5.1	5
125	In Vitro Pharmacodynamics of Vancomycin against Methicillin-Susceptible and -Resistant <i>Staphylococcus aureus</i> : Considering the Variability in Observed Tissue Exposure. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 955-61	5.9	5
124	Pharmacokinetics of Cefazolin and Vancomycin in Infants Undergoing Open-Heart Surgery With Cardiopulmonary Bypass. <i>Anesthesia and Analgesia</i> , 2019 , 128, 935-943	3.9	5
123	Comparative efficacy of human-simulated epithelial lining fluid exposures of tedizolid, linezolid and vancomycin in neutropenic and immunocompetent murine models of staphylococcal pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 970-977	5.1	5
122	Detection of Piperacillin-Tazobactam-Resistant/Pan- β -Lactam-Susceptible <i>Escherichia coli</i> with Current Automated Susceptibility Test Systems. <i>Infection Control and Hospital Epidemiology</i> , 2017 , 38, 379-380	2	4
121	Anti-staphylococcal activity resulting from epithelial lining fluid (ELF) concentrations of amikacin inhale administered via the pulmonary drug delivery system. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2017 , 16, 2	6.2	4
120	Humanized Exposures of a β -Lactam- β -Lactamase Inhibitor, Tazobactam, versus Non- β -Lactam- β -Lactamase Inhibitor, Avibactam, with or without Colistin, against <i>Acinetobacter baumannii</i> in Murine Thigh and Lung Infection Models. <i>Pharmacology</i> , 2018 , 101, 255-261	2.3	4
119	Recovery of Gram-Negative Bacteria from Aerobic Blood Culture Bottles Containing Antibiotic Binding Resins after Exposure to β -Lactam and Fluoroquinolone Concentrations. <i>Journal of Clinical Microbiology</i> , 2019 , 57,	9.7	4
118	Humanized tissue pharmacodynamics of cefazolin against commonly isolated pathogens in skin and skin structure infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 2443-7	5.1	4
117	Validation of a Dosing Strategy for Cefazolin for Surgery Requiring Cardiopulmonary Bypass. <i>Surgical Infections</i> , 2015 , 16, 829-32	2	4

116	Comparison of clarithromycin and ciprofloxacin therapy for <i>Bacillus anthracis</i> Sterne infection in mice with or without (60)Co gamma-photon irradiation. <i>Journal of Medical Microbiology</i> , 2005 , 54, 1157-1162	3.2	4
115	Antibacterials for the prophylaxis and treatment of bacterial endocarditis in children. <i>Paediatric Drugs</i> , 2001 , 3, 703-18	4.2	4
114	The effect of fleroxacin and ciprofloxacin on the pharmacokinetics of multiple dose caffeine. <i>Drugs</i> , 1995 , 49 Suppl 2, 357-9	12.1	4
113	Human-Simulated Antimicrobial Regimens in Animal Models: Transparency and Validation Are Imperative. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	4
112	1302. Cefiderocol Population Pharmacokinetics and Probability of Target Attainment in Plasma and Epithelial Lining Fluid in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infections. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S665-S665	1	4
111	An exploratory study to evaluate <i>Clostridium difficile</i> polymerase chain reaction ribotypes and infection outcomes. <i>Infection and Drug Resistance</i> , 2016 , 9, 143-8	4.2	4
110	Evaluation of a disease state management guideline for urinary tract infection. <i>International Journal of Antimicrobial Agents</i> , 2016 , 47, 451-6	14.3	4
109	Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 64,	5.9	4
108	Is One Sample Enough? β -Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	4
107	Evaluation of Linezolid Pharmacokinetics in Critically Ill Obese Patients with Severe Skin and Soft Tissue Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65,	5.9	4
106	Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against <i>Pseudomonas aeruginosa</i> from patients with cystic fibrosis. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2021 , 20, 9	6.2	4
105	Development of an HPLC-MS/MS method for the determination of ceftolozane/tazobactam in bronchoalveolar lavage fluid. <i>Future Science OA</i> , 2019 , 5, FSO352	2.7	3
104	Demography and burden of care associated with patients readmitted for urinary tract infection. <i>Journal of Microbiology, Immunology and Infection</i> , 2015 , 48, 517-24	8.5	3
103	Tissue penetration and exposure of cefepime in patients with diabetic foot infections. <i>International Journal of Antimicrobial Agents</i> , 2016 , 47, 247-8	14.3	3
102	In vitro microdialysis membrane efficiency of broad-spectrum antibiotics in combination and alone. <i>Clinical Pharmacology: Advances and Applications</i> , 2014 , 6, 97-101	1.5	3
101	Clinical exposure-response relationship of cefepime/taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 ,	5.1	3
100	1311. Intrapulmonary Pharmacokinetics of Cefiderocol in Hospitalized and Ventilated Patients Receiving Standard of Care Antibiotics for Bacterial Pneumonia. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S668-S668	1	3
99	Development of an HPLC Method for the Determination of Meropenem/Vaborbactam in Biological and Aqueous Matrixes. <i>Journal of Chromatographic Science</i> , 2020 , 58, 726-730	1.4	3

98	1405. Efficacy of the Human-Simulated Regimen (HSR) of Cefepime (FEP)/VNRX-5133 Combination Against Serine β -Lactamase-Producing Gram-negative Bacteria in the Neutropenic Murine Thigh Infection Model. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S432-S433	1	3
97	Evaluation of a Phenotypic Algorithm to Direct Carbapenemase Testing in : Validation in a Multicenter German Cohort. <i>Microbial Drug Resistance</i> , 2021 , 27, 1243-1248	2.9	3
96	Optimised cefiderocol exposures in a successfully treated critically ill patient with polymicrobial <i>Stenotrophomonas maltophilia</i> bacteraemia and pneumonia receiving continuous venovenous haemodiafiltration. <i>International Journal of Antimicrobial Agents</i> , 2021 , 58, 106395	14.3	3
95	Treatment with appropriate antibiotic therapy in community-acquired respiratory tract infections. <i>American Journal of Managed Care</i> , 2004 , 10, S381-8	2.1	3
94	Physical compatibility of ceftolozane-tazobactam with selected i.v. drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2017 , 74, e47-e54	2.2	2
93	Where should antibiotic gradient diffusion strips be crossed to assess synergy? A comparison of the standard method with a novel method using steady-state antimicrobial concentrations. <i>International Journal of Antimicrobial Agents</i> , 2019 , 53, 698-702	14.3	2
92	Precision medicine for the diagnosis and treatment of carbapenem-resistant Enterobacterales: time to think from a different perspective. <i>Expert Review of Anti-Infective Therapy</i> , 2020 , 18, 721-740	5.5	2
91	Subcutaneous cefazolin to reduce surgical site infections in a porcine model. <i>Journal of Surgical Research</i> , 2018 , 224, 156-159	2.5	2
90	Pharmacodynamic profiling of modithromycin: assessment in a pneumococcal murine pneumonia model. <i>International Journal of Antimicrobial Agents</i> , 2014 , 43, 540-6	14.3	2
89	Inhaled Antimicrobials for Ventilator-Associated Pneumonia: Practical Aspects. <i>Drugs</i> , 2017 , 77, 1399-1412.	12.1	2
88	Pharmacokinetics of ticlopidine in the rabbit. <i>Journal of Pharmacy and Pharmacology</i> , 1999 , 51, 393-6	4.8	2
87	Reply to Double-Carbapenem Therapy Not Proven To Be More Active than Carbapenem Monotherapy against KPC-Positive <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 4038-4038	5.9	2
86	Infusion phlebitis: relative incidence associated with cefuroxime administered by intermittent and continuous infusion. <i>Clinical Drug Investigation</i> , 1998 , 15, 531-5	3.2	2
85	Imipenem/Cilastatin/Relebactam Alone and in Combination against in the Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	2
84	Activity of WCK 4282 (High-Dose Cefepime/Tazobactam) against Serine- β -Lactamase-Producing and <i>Pseudomonas aeruginosa</i> in the Neutropenic Murine Lung Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65,	5.9	2
83	Comparative in vivo activity of human-simulated plasma and epithelial lining fluid exposures of WCK 5222 (cefepime/zidebactam) against KPC- and OXA-48-like-producing <i>Klebsiella pneumoniae</i> in the neutropenic murine pneumonia model. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2310-2316	5.1	2
82	682. In Vivo Pharmacodynamics of VNRX-7145 in the Neutropenic Murine Thigh Infection Model When Administered in Combination with Humanized Exposures of Twice Daily Ceftibuten (CTB) Against Serine β -Lactamase-Producing Enterobacteriaceae (SBL-EB). <i>Open Forum Infectious Diseases</i> , 2019 , 6, S311-S311	1	2
81	Single β -lactams versus combinations as empiric therapy for infections with : assessing the susceptibility. <i>Infectious Diseases</i> , 2020 , 52, 33-38	3.1	2

80	Efficacy of human-simulated exposures of meropenem/vaborbactam and meropenem against OXA-48 β -lactamase-producing Enterobacterales in the neutropenic murine thigh infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 184-188	5.1	2
79	Variability in Emergency Medicine Provider Decisions on Hospital Admission and Antibiotic Treatment in a Survey Study for Acute Bacterial Skin and Skin Structure Infections: Opportunities for Antimicrobial Stewardship Education. <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofy206	1	2
78	Carbapenemase-producing -an emerging challenge.. <i>Emerging Microbes and Infections</i> , 2022 , 11, 811-814	18.9	2
77	Physical compatibility of isavuconazonium sulfate with select i.v. drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2017 , 74, e55-e63	2.2	1
76	Assessment of Meropenem and Vaborbactam Room Temperature and Refrigerated Stability in Polyvinyl Chloride Bags and Elastomeric Devices. <i>Clinical Therapeutics</i> , 2020 , 42, 606-613	3.5	1
75	Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration. <i>BMC Infectious Diseases</i> , 2020 , 20, 74	4	1
74	In vivo efficacy of humanized high dose meropenem and comparators against Pseudomonas aeruginosa isolates producing verona integron-encoded metallo- β -lactamase (VIM). <i>Heliyon</i> , 2016 , 2, e00121	3.6	1
73	In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 222-8	5.9	1
72	Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. <i>Clinical Therapeutics</i> , 2019 , 41, 2162-2170	3.5	1
71	Falsely elevated vancomycin-concentration values from enzyme immunoassay leading to treatment failure. <i>American Journal of Health-System Pharmacy</i> , 2020 , 77, 9-13	2.2	1
70	Supporting the ceftaroline fosamil/avibactam Enterobacteriaceae breakpoint determination using humanised in vivo exposures in a thigh model. <i>International Journal of Antimicrobial Agents</i> , 2014 , 44, 508-13	14.3	1
69	Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function. <i>Journal of Pharmacy Practice</i> , 2017 , 30, 593-599	1.3	1
68	Pharmacodynamic Target Attainment for Meropenem and Piperacillin/Tazobactam Using a PK/PD-based Dosing Calculator in Critically Ill Patients. <i>Open Forum Infectious Diseases</i> , 2017 , 4, S27-S27 ¹		1
67	Defining Extended Spectrum β -Lactamases: Implications of Minimum Inhibitory Concentration-Based Screening Versus Clavulanate Confirmation Testing. <i>Infectious Diseases and Therapy</i> , 2015 , 4, 513	6.2	1
66	Bugs versus drugs: what is the pharmacist's challenge?. <i>American Journal of Health-System Pharmacy</i> , 2008 , 65, S2-3	2.2	1
65	IV to Oral Conversion Programs for Anti-Infectives in the United States: Prevalence and Characteristics. <i>Hospital Pharmacy</i> , 2004 , 39, 1069-1075	1.1	1
64	Maximizing outcomes in respiratory tract infections in the age of resistance. <i>Pharmacotherapy</i> , 2002 , 22, 1S; discussion 30S-32S	5.8	1
63	In vitro Time Kill of Trimethoprim/Sulfamethoxazole against versus using Cation Adjusted Muller Hinton Broth and ISO-Sensitest Broth.. <i>Antimicrobial Agents and Chemotherapy</i> , 2022 , aac0216721	5.9	1

62	Minocycline pharmacodynamics against <i>Stenotrophomonas maltophilia</i> in the neutropenic murine infection model: implications for susceptibility breakpoints.. <i>Journal of Antimicrobial Chemotherapy</i> , 2022 ,	5.1	1
61	Stability of Ertapenem 100 mg/mL at Room Temperature. <i>Canadian Journal of Hospital Pharmacy</i> , 2016 , 69, 256-9	0.5	1
60	Efficacy and Safety of Eravacycline in Obese Patients: A Post Hoc Analysis of Pooled Data From the IGNITE1 and IGNITE4 Clinical Trials. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa548	1	1
59	Impact of Intraoperative Cell Salvage on Concentrations of Antibiotics Used for Surgical Prophylaxis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	1
58	Cefiderocol Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemodiafiltration. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab252	1	1
57	Comment on: An update on cefepime and its future role in combination with novel β -lactamase inhibitors for MDR Enterobacterales and <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 3326-3327	5.1	1
56	Application of "Precision Medicine" Through the Molecular Characterization of Extensively Drug Resistant (XDR) <i>Klebsiella pneumoniae</i> in a Multivisceral Transplant Candidate. <i>Open Forum Infectious Diseases</i> , 2016 , 3,	1	1
55	1550. PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase (CF-301) in Pre-Clinical Models. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S565-S566	1	1
54	The Ongoing Challenge with NDM-Harboring in Murine Infection Models. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65,	5.9	1
53	Pharmacodynamics of Ceftibuten: An Assessment of an Oral Cephalosporin against Enterobacterales in a Neutropenic Murine Thigh Model. <i>Antibiotics</i> , 2021 , 10,	4.9	1
52	1336. Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) Against Carbapenems-Resistant <i>Acinetobacter baumannii</i> (CR-ACBN) in the Neutropenic Murine Thigh Infection Model. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S408-S408	1	1
51	1368. Assessment of the In Vivo Efficacy of Human-Simulated Epithelial Lining Fluid (ELF) Exposure of Meropenem/Nacubactam (MEM/NAC) Combination Against β -Lactamase-Producing Enterobacteriaceae in Neutropenic Lung Infection Model. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S419-S419	1	1
50	Optimizing Antibiotic Administration for Pneumonia. <i>Clinics in Chest Medicine</i> , 2018 , 39, 837-852	5.3	1
49	Efficacy assessment of lysin CF-296 in addition to daptomycin or vancomycin against <i>Staphylococcus aureus</i> in the murine thigh infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2622-2628	5.1	1
48	Reply to Rennie, "Zinc Concentration Affects Metallo-Beta-Lactamase Susceptibility Testing of ". <i>Journal of Clinical Microbiology</i> , 2021 , 59, e0121121	9.7	1
47	Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> : Implications for Dose Optimization. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65, e0120421	5.9	1
46	Ceftolozane/tazobactam for refractory <i>P. aeruginosa</i> endocarditis: A case report and pharmacokinetic analysis. <i>Journal of Infection and Chemotherapy</i> , 2022 , 28, 87-90	2.2	1
45	Phenotypic/Genotypic Profile of OXA-10-Like-Harboring, Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> : Using Validated Pharmacokinetic/Pharmacodynamic Models To Further Evaluate Enzyme Functionality and Clinical Implications. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65, e0127421	5.9	1

44	In vivo activity of WCK 4282 (high-dose cefepime/tazobactam) against serine β -lactamase-producing Enterobacterales and <i>Pseudomonas aeruginosa</i> in the neutropenic murine thigh infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 993-1000	5.1	1
43	Comparison of Zinc Concentrations in the Broth of Commercial Automated Susceptibility Testing Devices (Vitek 2, MicroScan, BD Phoenix, and Sensititre).. <i>Microbiology Spectrum</i> , 2022 , e0005222	8.9	1
42	Multicenter, Prospective Validation of a Phenotypic Algorithm to Guide Carbapenemase Testing in Carbapenem-Resistant Using the ERACE-PA Global Surveillance Program.. <i>Open Forum Infectious Diseases</i> , 2022 , 9, ofab617	1	1
41	Reply to Cheng and Chuang. <i>Clinical Infectious Diseases</i> , 2019 , 69, 903-904	11.6	0
40	1317. Pharmacokinetics (PK) of Ampicillin-Sulbactam (SAM) during Orthotopic Liver Transplantation (OLT). <i>Open Forum Infectious Diseases</i> , 2020 , 7, S670-S670	1	0
39	Evaluation of Metallo- β -Lactamase Susceptibility Testing in a Physiologic Medium. <i>Microbiology Spectrum</i> , 2021 , e0167021	8.9	0
38	A Novel Dosing Strategy of Ceftolozane/Tazobactam in a Patient Receiving Intermittent Hemodialysis. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab238	1	0
37	In vitro synergy of ticarcillin/clavulanate in combination with aztreonam and ceftolozane/tazobactam against SPM-1-producing <i>Pseudomonas aeruginosa</i> strains. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021 , 100, 115343	2.9	0
36	Pharmacokinetics, Tissue Distribution, and Efficacy of VIO-001 (Meropenem/Piperacillin/Tazobactam) for Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia in Immunocompetent Rabbits with Chronic Indwelling Vascular Catheters. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65, e0116821	5.9	0
35	1087. Imipenem-Cilastatin-Relebactam (I/R) Pharmacokinetics (PK) in Critically Ill Patients with Augmented Renal Clearance (ARC). <i>Open Forum Infectious Diseases</i> , 2021 , 8, S635-S635	1	0
34	Pharmacokinetics and Time above the MIC Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO).. <i>International Journal of Antimicrobial Agents</i> , 2022 , 106603	14.3	0
33	Critique of prevention of pneumococcal disease in high risk adults: A pharmacist-based assessment of adult immunization protocols in clinical practice. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2019 , 2, 444-445	1.4	
32	In Vitro Antibacterial Activity of Ceftolozane/Tazobactam (C/T) Alone and in Combination with other Antimicrobial Agents against Multidrug-Resistant (MDR) <i>Pseudomonas aeruginosa</i> (PSA). <i>Open Forum Infectious Diseases</i> , 2017 , 4, S298-S299	1	
31	Clinical use comparison of a semiautomated PCR with fluorescent ribotyping for typing of <i>Clostridium difficile</i> . <i>Archives of Microbiology</i> , 2017 , 199, 317-323	3	
30	Spatio-temporal Activity of Human-Simulated Exposures of Meropenem (MEM) and Ceftolozane (TOL) on <i>Pseudomonas aeruginosa</i> Biofilms. <i>Open Forum Infectious Diseases</i> , 2017 , 4, S294-S294	1	
29	Pharmacotherapy of Complicated Urinary Tract and Intra-abdominal Infections with Doripenem. <i>Clinical Medicine Therapeutics</i> , 2009 , 1, CMT.S2062		
28	Influence of automated screening and confirmation of extended-spectrum beta-lactamase-producing members of the Enterobacteriaceae on prescribing of antibiotics. <i>Journal of Medical Microbiology</i> , 2008 , 57, 1147-1151	3.2	
27	Serum bactericidal activity of ceftriaxone plus metronidazole against common intra-abdominal pathogens. <i>American Journal of Health-System Pharmacy</i> , 1994 , 51, 1782-1787	2.2	

26	1103. Minocycline (MIN) Pharmacodynamics (PD) against <i>Stenotrophomonas maltophilia</i> (STM) in a Neutropenic Murine Thigh Infection Model. <i>Open Forum Infectious Diseases</i> , 2021 , 8, S643-S643	1
25	Impact of Order-Set Modifications and Provider Education Following Guideline Updates on Broad-Spectrum Antibiotic Use in Patients Admitted With Community Acquired Pneumonia. <i>Hospital Pharmacy</i> ,001857872110557	1.1
24	1264. Assessment of In Vivo Efficacy of CF-296 in addition to Vancomycin (VAN) and Daptomycin (DAP) against <i>Staphylococcus aureus</i> in the Neutropenic Murine Thigh Infection Model. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S648-S649	1
23	1308. Ex vivo Impact of Autologous Blood Transfusion (ABT) on Concentrations of Antibiotics used for Surgical Prophylaxis. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S667-S667	1
22	1245. In Vivo Efficacy of WCK 4282 (High Dose Cefepime [FEP]-Tazobactam [TZB]) Against β -Lactamase-Producing (BLP) Gram-Negative Bacteria in a Neutropenic Murine Pneumonia Model. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S641-S641	1
21	13. Evaluation of Etest for Antibiotic Susceptibility and Minimum Inhibitory Concentration (MIC) Agreement Against <i>Pseudomonas Aeruginosa</i> (psa) from Patients with Cystic Fibrosis (CF). <i>Open Forum Infectious Diseases</i> , 2020 , 7, S7-S8	1
20	656. Development and Application of a Pragmatic Algorithm for the Detection of Carbapenemase-Producing <i>Pseudomonas aeruginosa</i> (CP-PA). <i>Open Forum Infectious Diseases</i> , 2020 , 7, S384-S385	1
19	1312. Metallo- β -Lactamase-Producing Enterobacterales (MBL-EB): Is it Time to Rethink Our Assessment Tools?. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S668-S668	1
18	1602. Comparative Activity of Ceftolozane-Tazobactam (C/T) and Ceftazidime-Avibactam (CZA) against <i>Pseudomonas aeruginosa</i> (PSA) from Patients with Cystic Fibrosis (CF). <i>Open Forum Infectious Diseases</i> , 2020 , 7, S797-S797	1
17	1244. Assessment of the In Vivo Activity of Human-Simulated Exposure of WCK 4282 (High Dose Cefepime [FEP]-Tazobactam [TZB]) against Enterobacterales (EB) and <i>Pseudomonas aeruginosa</i> (PA) in the Neutropenic Murine Thigh Infection Model. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S640-S641	1
16	1309. Imipenem/Cilastatin/Relebactam (I/R) Alone and in Combination against <i>Pseudomonas aeruginosa</i> (PSA) in the In Vitro Pharmacodynamic Model. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S667-S667	1
15	1299. In Vitro-In Vivo Discordance with β -Lactams against Metallo- β -Lactamase-Producing Enterobacterales: Implications for Susceptibility Testing. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S664-S664	1
14	1215. Evaluation of the Carba-R NxG Assay in a Global Challenge Set of <i>Pseudomonas aeruginosa</i> . <i>Open Forum Infectious Diseases</i> , 2020 , 7, S629-S629	1
13	1296. Efficacy of Human-Simulated Exposures of Meropenem/Vaborbactam (MVB) and Meropenem (MEM) against OXA-48 β -Lactamase-producing Enterobacterales in the Neutropenic Murine Thigh Infection Model. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S663-S663	1
12	Development and characterization of a new swine model of invasive pneumococcal pneumonia. <i>Lab Animal</i> , 2021 , 50, 327-335	0.4
11	Optimizing Efficacy in CARTIs: introduction. <i>Annals of Pharmacotherapy</i> , 2004 , 38, S7	2.9
10	What is the 360-degree approach to defining success for VAP?. <i>Journal of Managed Care Pharmacy</i> , 2009 , 15, S3-4	
9	Bactericidal In Vitro Activity of a Tissue-Achievable Concentration of Cefazolin against Methicillin-Resistant. <i>Surgical Infections</i> , 2021 , 22, 447-449	2

8	Murine Model for Measuring Effects of Humanized-Dosing of Antibiotics on the Gut Microbiome.. <i>Frontiers in Microbiology</i> , 2022 , 13, 813849	5-7
7	1109. Pharmacokinetics and Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO). <i>Open Forum Infectious Diseases</i> , 2021 , 8, S646-S646	1
6	58. Impact of Order-set Modifications and Provider Education on Broad-Spectrum Antibiotic Use in Patients Admitted with Community Acquired Pneumonia. <i>Open Forum Infectious Diseases</i> , 2021 , 8, S147-S148	1
5	65. In Vivo Efficacy of Human Simulated Minocycline (MIN) against <i>Stenotrophomonas maltophilia</i> (STM). <i>Open Forum Infectious Diseases</i> , 2021 , 8, S44-S44	1
4	1241. In Vivo Efficacy of Meropenem Against Metallo- β -Lactamase (MBL)-Harboring <i>Pseudomonas aeruginosa</i> and Correlation to In Vitro Susceptibility Upon Addition of EDTA. <i>Open Forum Infectious Diseases</i> , 2021 , 8, S710-S710	1
3	Evaluation of high-concentration EDTA-modified carbapenemase inactivation method (eCIM) for SPM-producing <i>Pseudomonas aeruginosa</i> .. <i>Archives of Microbiology</i> , 2021 , 204, 55	3
2	Assessment of sustained efficacy and resistance emergence under human-simulated exposure of cefiderocol against using chemostat and murine infection models.. <i>JAC-Antimicrobial Resistance</i> , 2022 , 4, dlac047	2.9
1	In vitro potency of amikacin against carbapenem-resistant <i>Pseudomonas aeruginosa</i> : A target for nebulization strategy?. <i>Brazilian Journal of Infectious Diseases</i> , 2022 , 26, 102355	2.8